Accepted for publication (PostPrint)
CHEMTECH 2014: Chemical Engineering & Chemical Technologies Conference
Osteoporosis is a progressive bone disease that over time, bone mass, and therefore bones strength, is decreased, due to depletion of calcium and bone protein. So, bones become fragile and break easily. The unique ability of human parathyroid hormone (hPTH) as a bone anabolic agent, to increase bone density makes it a promising anabolic agent in the treatment of osteoporosis. Parathyroid hormone secreted by parathyroid chief cells is composed of 84 amino acids act as one of the major hormones maintaining calcium homeostasis. Anabolic agents directly stimulate bone formation and improve the microarchitecture of bone. Hence, they have the potential to increase bone mass by promoting the growth of new bone greater extent than antiresorptives that inhibit bone resorption. N-terminal fragment (amino acids 1–34) of human parathyroid hormone was regarded to cover most of the hormonal actions of the intact human parathyroid hormone named teriparatide and is currently the only FDA approved anabolic medication for osteoporosis. According to some reports, the C-terminal region of the full-length PTH (1–84) may play an important role in its biological function. The C-terminus of PTH can regulate calcium concentration released from bone through binding to a different PTH receptor specific for the C-terminus. The aim of this study was to express and produce the recombinant PTH protein (1-84) in E.coli.
Majdi, Sadegh; Esfahani, Elahe; Amani, Hossein; Najaf pour D, Ghasem; and Shahbazi, Majid, "Subcloning and expression of recombinant human parathyroid hormone rhPTH by fusion strategy in E.coli" (2014). Henry M. Rowan College of Engineering Faculty Scholarship. 78.